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Abstract
Background: Photodynamic therapy (PDT) involves systemic or topical administration of a lesion-
localizing photosensitizer or its precursor, followed by irradiation of visible light to cause singlet
oxygen-induced damage to the affected tissue. A number of mechanisms seem to be involved in the
protective responses to PDT, including activation of transcription factors, heat shock proteins,
antioxidant enzymes and apoptotic pathways.
Results: In this study, we address the effects of a destructive/lethal hexaminolevulinate (HAL)
mediated PDT dose on the transcriptome by using transcriptional exon evidence oligo microarrays.
Here, we confirm deviations in the steady state expression levels of previously identified early
defence response genes and extend this to include unreported PDT inducible gene groups, most
notably the metallothioneins and histones. HAL-PDT mediated stress also altered expression of
genes encoded by mitochondrial DNA (mtDNA). Further, we report PDT stress induced
alternative splicing. Specifically, the ATF3 alternative isoform (deltaZip2) was up-regulated, while
the full-length variant was not changed by the treatment. Results were independently verified by
two different technological microarray platforms. Good microarray, RT-PCR and Western
immunoblotting correlation for selected genes support these findings.
Conclusion: Here, we report new insights into how destructive/lethal PDT alters the
transcriptome not only at the transcriptional level but also at post-transcriptional level via
alternative splicing.
Background
Photodynamic therapy (PDT) combines a light-activated
drug with non-thermal light to cause selective damage to
the target tissue [1]. The major mechanism of action of
PDT has been shown to be induction of oxidative stress
[2,3]. It has also been shown that PDT-mediated oxidative
stress induces a transient increase in the early response
genes FOS, JUN, MYC, and EGR1 [4,5], heat shock pro-
teins (HSPs) [6-9], as well as SOD2, LUC7A, CASP8, and
DUSP1 [10]. Furthermore, relevant information exists
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oxidative stress [5,11-18]. Signaling pathways influenced
by PDT have not been fully elucidated, although a
number of studies have addressed this issue [5,10,19].
Moreover, relatively little is known regarding global gene
activity, particularly when oxidative stress becomes exces-
sive, as is the case for PDT. Both clonogenic survival of
cells from tumors after in vivo PDT treatment [20] and
resistance to aminolevulinic acid (ALA)-mediated PDT
[21] have been reported previously. Intrinsic cell sensitiv-
ity to PDT has been proposed [20] to be an important
component in the mechanism that leads to tumor
response following PDT treatment in vivo.
A better understanding of the mechanics of the destructive
PDT could facilitate further the development of this ther-
apy. Oxidative stress evokes many intracellular events
including apoptosis [22]. Modulating the anti-apoptosis
factors that are activated by survival signaling may
improve efficacy of the therapy. Under conditions where
oxidative stress is the initiating stimulus for apoptosis, it
is assumed to simply trigger cell death as a result of cumu-
lative oxidative damage. However, accumulating evidence
now suggests that reactive oxygen species (ROS) may act
as signaling molecules for the initiation and execution of
the apoptotic death program in many, if not all, current
models of apoptotic cell death [23,24]. Signaling by ROS
would not appear to be random, as previously assumed,
but targeted at specific metabolic and signal transduction
cellular components [25].
Here, we address the effects of a destructive/lethal PDT
dose on the transcriptome by using transcriptional exon
evidence oligo microarrays. This dose induces high levels
of cytotoxicity and is expected to have significant impact
on gene expression patterns. The expression alterations
were observed by investigating both early responses, and
responses post mobilization of major response pathways.
We show that high levels of cellular cytotoxicity have a
direct effect on cellular transcription levels and impair
metabolic processes. Alternative splicing represents a key
event in the control of gene expression [26-30]. Here, we
tested to what extent mitochondrial damage caused by
HAL-PDT modulates alternative splicing in a global man-
ner.
Results and discussion
Rationale for selection of experimental parameters
Sensitizer
5-Aminolevulinic acid (ALA), a precursor to porphyrins, is
effective and widely used for PDT of a number of diseases
[31-34]. However, a significant shortcoming of ALA is its
limited ability to cross certain biological barriers (e.g. cel-
lular membranes), probably due to its low lipid solubility.
In contrast, ALA esters are more lipophilic and pass more
easily through biological membranes than ALA itself.
Hexaminolevulinate (HAL) is a hexyl ester of ALA with a
higher lipophilicity. HAL has been shown to be 50–100
times more efficient than ALA at inducing cellular porphy-
rin formation with a high selectivity [35], and has been
approved by the European Union for photodetection of
bladder cancer. Thus, HAL is a promising compound for
PDT therapy. On this basis, it is reasonable to assume that
the mechanisms of action of ALA and HAL are compara-
ble, and that gene expression profiles should be very sim-
ilar. Therefore, only HAL was chosen for this study.
Cell line
Studies are now in progress to test the use of PDT for sev-
eral types of pre-cancerous conditions and cancer, includ-
ing cancers of the skin, cervix, bladder, prostate, bile duct,
pancreas, stomach, brain, head and neck, as well as lym-
phoma. PDT using topically applied ALA was first
reported for the treatment of cutaneous T-cell lymphoma
(CTCL) in 1994. Since then, there have been several
reports of its usefulness in treating this disease [33,36-39].
The role of PDT in CTCL to date has been in the treatment
of individual patches, plaques, and tumors that have not
responded to the other forms of skin directed therapy.
While several PDT protocols have been evaluated, further
studies remain in order to define the optimal use of PDT
in treating patients with CTCL. Moreover, the use of PDT
for ex vivo purging of autologous bone marrow graft has
been proposed [40]. High-dose chemotherapy supported
by hematopoietic stem cells transplantation (HSCT)
presents an effective way to cure lymphoma/leukemia.
Although autologous HSCT has several advantages over
allogenous HSCT, autografts may harbor residual occult
malignant cells that can cause a tumor relapse after being
reinfused to the patient. It is therefore desirable to remove
the residual neoplastic cells from the autograft before
being applied. The ability of malignant cells to selectively
accumulate photosensitizers offers the possibility of using
PDT in bone marrow purging. Recently, a study of the
purging effects of PDT in leukemic cells mixed with nor-
mal bone marrow MNCs was published [41].
Here, we aimed to map general responses on gene expres-
sion after PDT therapy. Therefore we employed the Jurkat
human T-cell leukemia cell line that previously has been
used in multiple PDT-studies. The induction of apoptosis
through translocation of apoptosis-inducing factor
[42,43] and caspase-3-like activation has been demon-
strated for this cell line. Also, other sensitizers in PDT ther-
apy have been shown to induce apoptosis in Jurkat cells
[32,44-46].
Dose and time course
The aim of this study was to determine the gene expres-
sion state of the cell in response to PDT immediately priorPage 2 of 20
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we measured gene signatures that were likely to represent
a combination of both protective and pro-apoptotic sig-
nals. The characterization of the transcriptome at early
stages (1 h and 2 h) was chosen to reveal the state of the
cell prerequisites to the execution of the cell death pro-
gram.
It has been previously demonstrated that the appearance
of cytoplasmic mRNA degradation products occur 4–8 h
after induction of apoptosis, independent of the apoptotic
signal and the cell line used [47]. The purity and integrity
of the RNA are critical for the overall success of RNA-based
analysis, including gene expression profiling. For this rea-
sons, the late (4 h) time point was selected to provide an
insight into the later stages of this process, but still retain
a sufficient numbers of viable cells and RNA integrity nec-
essary for the technical execution of the analysis. In this
study, the integrity of total RNA was measured by micro-
capillary electrophoresis and the degree of degradation
was determined (data not shown). With the starting
amount of cells kept equal across experiments, a time
dependent decrease of the total amount of isolated total
RNA was obtained. No compromise in the integrity of the
RNA was observed. This indicates the effective removal of
the dead cell fraction by the wash/centrifugation step, fol-
lowing degradation of leaked RNA.
PDT is a cytotoxic therapy approach, where the dose in
therapeutic settings is selected to kill 100% of the target
cells. Therefore, a lethal dose (LD) relevant to therapeutic
settings was chosen for the study. Lethal and sub lethal
doses have been employed in a number of reports that
investigated the apoptotic pathways induced by PDT
[42,43,48]. The cell survival after HAL-PDT was deter-
mined to select the killing dose specific for the Jurkat cell
line. Fig. 1A shows the decreased cell survival with
increased light doses. Approximately 90% of the cells
were killed at 4 h post PDT with the light dose 240 mJ/
cm2, while 96% of the cells treated with light alone and
98% of the cells treated with HAL alone were still viable
(data not shown). The light dose of 160 mJ/cm2 that cor-
responds to LD 75% at 4 h post HAL-PDT was selected for
microarray experiments. The viability of cells treated with
LD 75% dose was measured at 1, 2 and 4 h after HAL-PDT
(Fig. 1B). There was no change in cell viability observed at
1 h, while the viable cell fraction was reduced to 70% and
30% at 2 h and 4 h post treatment.
Survival fraction of cells was measured at 4 h after PDT when irradiation was performed with different light doses (A)Figure 1
Survival fraction of cells was measured at 4 h after PDT when irradiation was performed with different light doses (A). Cell sur-
vival was measured at 1, 2 and 4 h after PDT with the light dose of 160 mJ/cm2 (B). Bars are SE based on three independent 
experiments with 3 parallels in each.Page 3 of 20
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For gene expression analysis, Jurkat cells were treated with
HAL-PDT, and total RNA was harvested from triplicate
samples of non-treated and treated cells at 1, 2 and 4 h
after HAL-PDT. Gene expression levels in HAL-PDT
treated cells relative to non-treated cells were determined
by oligo microarrays that contained a total of 44,308 oli-
gos targeting human genes. The Venn diagram shows that
146 probes (103 unique Entrez gene IDs) exhibited signif-
icant changes (p < 0.05) 1 h after HAL-PDT treatment (Fig.
2A). The number of significantly altered probes/genes was
reduced to 68 probes (53 unique Entrez gene IDs) at 2 h
post treatment, with a subsequent large increase at 4 h,
with 15,762 probes (10,373 unique Entrez gene IDs). The
large number of genes with altered expression at the 4 h
time point might reflect a high degree of disturbance in
transcriptome within the pro-apoptotic cell. Therefore
these genes will be discussed separately as late response
genes.
Early responses
A total of 170 probes (124 unique Entrez gene IDs) were
altered at early (1 and 2 h) response (Fig. 2A). Of these
82.9% were up-regulated, i.e. 124 probes at 1 h and 61
probes at 2 h (Fig. 2B), while a total of 29 probes were
identified as down-regulated at early response (Fig. 2C).
Previously, we have reported on the stimulatory effects on
the transcriptome using a related treatment modality,
photochemical inhibition treatment (PCI) [49]. PCI is
based on photosensitizers with photochemical properties
similar to those utilized in PDT. However, a weaker dose
(LD 50%) is generally used, as the aim is not primarily to
cause general cell toxicity. Interestingly, when the lethal
PDT dose applied in the present study was compared to
those induced by PCI, several of the early altered genes
were identified as up-regulated with both modalities,
indicating that both moderate (PCI) and high level (PDT)
of oxidative stress are likely to invoke similar modulatory
pathways, albeit with very different effects at later time
points.
Of the total of 170 probes detected as altered at the two
early time points, 44 probes (32 unique Entrez gene IDs)
were identified as shared for both the 1 h and 2 h time
points in response to HAL-PDT. Among the early response
genes, mostly genes encoding proteins involved in the reg-
ulation of transcription processes were induced, such as v-
jun sarcoma virus 17 oncogene homolog (avian) (JUN),
jun B proto-oncogene (JUNB), v-maf musculoaponeu-
rotic fibrosarcoma oncogene homolog B (avian) (MAFB),
RNA-binding region (RNP1, RRM) containing 2
(RNPC2), SRY (sex determining region Y)-box 4 (SOX4),
tribbles homolog 3 (Drosophila) (TRIB3), Kruppel-like
factor 6 (KLF6), zinc finger protein 184 (Kruppel-like)
(ZNF184), activating transcription factor 3 (ATF3), BTG
family, member 2 (BTG2). While inhibitor of DNA bind-
ing 3, dominant negative helix-loop-helix protein (ID3)
and v-myc myelocytomatosis viral oncogene homolog
Venn diagrams of differentially altered genes/probes in response to HAL-PDTFigure 2
Venn diagrams of differentially altered genes/probes in response to HAL-PDT. A, includes up-regulated and down-regulated; B, 
only up-regulated; C, only down-regulated genes/probes at 1, 2 and 4 h time course. Each circle represents one time point as 
indicated. A total number of differentially expressed genes in the group are given in the parentheses. The intersections indicate 
numbers of genes/probe that are shared between the different time points, i.e. the genes that were steady induced. The 
number in the right bottom of each square indicates a total post processed and analyzed number of genes/probes minus the 
number of differentially expressed genes presented in circles.Page 4 of 20
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gene expression data, the protein products of MYC were
found to be reduced, while JUN had increased levels at 2
h and 4 h after HAL-PDT (Fig. 3). Over-expression of ATF3
was seen until 2 h following PDT, but the protein level
appears to be decreased at 4 h, probably due to a short
half-life (about 30–60 min) of ATF proteins [50]. Several
genes belonging to gene ontology group of negative regu-
lation of cell cycle were up-regulated, such as cyclin-
dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B),
protein phosphatase 1, regulatory (inhibitor) subunit 15A
(PPP1R15A) and sestrin 2 (SESN2). Genes coding for pro-
teins of apoptosis regulation were also found to be up-reg-
ulated, such as heat shock 70 kDa protein 1B (HSPA1B),
tumor necrosis factor (TNF superfamily, member 2)
(TNF), tribbles homolog 3 (Drosophila) (TRIB3), protein
phosphatase 1, regulatory (inhibitor) subunit 15A
(PPP1R15A), nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (NFKBIA).
Histone related genes
Of the 170 probes detected as early genes (124 unique
Entrez gene IDs), 53 genes were identified as involved in
nucleosome assembly and belonged to the histone family
of genes (Fig. 4). Interestingly, various subtypes of the
linker histone, H1 (totally 49 histone 1 subtypes/forms),
were affected to a high degree by HAL-PDT. Six different
histone 2 subtypes/forms (HIST2H2AB, HIST2H2AC,
HIST2H2BE, HIST2H2AA, HIST2H3C, HIST2H4) and
histone 4, H4 (HIST4H4) were also up-regulated (Fig. 4).
Verification of MYC, ATF3 and JUN expression after HAL-PDT by Western blottingFigure 3
Verification of MYC, ATF3 and JUN expression after HAL-PDT by Western blotting. Cell extracts were prepared at at 1 h, 2 h 
and 4 h after HAL-PDT (A). Since PDT affected the expression of well-known house keeping proteins such actin (induced) and 
tubulin (repressed) the total protein content was measured and the gels were stained after electrophoresis, thus normalize 
against total protein content. The fold-changes obtained by the microarray analysis for the selected genes are presented for 
comparison. Fold-change of three repeated experiments presented as the mean ± St. Dev (B).Page 5 of 20
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Cluster of histone genes that were significantly altered in response to HAL-PDTFigure 4
Cluster of histone genes that were significantly altered in response to HAL-PDT. Horizontal stripes represent genes and col-
umns show treatment protocols. The log2-fold changes of gene ratios are color coded as shown in the bar. The three different 
columns represent repeated microarray experiments.
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condensation of chromatin, protects mammalian cell
DNA from radiation-induced strand breakage [51].
Recently, it was reported that the ZnTPPS(4) sensitizer,
when bound to cyclodextrin hpbeta CD, as used in PDT,
can induce DNA breaks [52]. Also, beta-carboline deriva-
tives (1,3,9-trisubstituted beta-carboline derivatives) were
demonstrated to distribute within the nucleus and inter-
calate into DNA, causing direct DNA damage through
photochemical reaction products in PDT [53]. Previously,
it was assumed that ALA-mediated PDT might not induce
a clear DNA-damage response, probably due to the fact
that HAL-induced porphyrins are localized in the mito-
chondria and bio-membraneous structures. Since singlet
oxygen, the main cytotoxic agent produced by light-acti-
vated sensitizers, has a lifetime of less than 0.05 µs, with a
maximal diffusion of 0.02 µm from the site of its produc-
tion [54], extra-nuclear components of the cells were orig-
inally expected to be the main targets of HAL-PDT.
However, it was subsequently demonstrated that light
activation of porphyrins derived from exogenous ALA
produced DNA oxidative damage in a dose dependent
manner [55-57]. The induction of histone genes might
indicate a complexing of histones with DNA, with result-
ing condensation of chromatin to protect DNA from HAL-
PDT caused by oxidative stress. The protective role of his-
tones in chromatin condensation as a response to stress
was recently challenged by Konishi at el [58], through the
proposal of a novel mechanism for cells to sense a specific
cellular stress with ignition of an apoptotic response to
eliminate damage. A specific isoform of the linker histone,
histone H1.2 (HIST1H1C), has been found to translocate
from the nucleus into the cytoplasm, where it induces the
release of cytochrome c from the mitochondria, with sub-
sequent apoptosis of the cell [58]. While all nuclear his-
tone H1 forms are released into the cytoplasm in a p53-
dependent manner after X-ray irradiation, only H1.2, but
not other H1 forms, induced cytochrome c release from
isolated mitochondria in a Bak-dependent manner [58].
The HIST1H1C form was among the early up-regulated
histone genes we found responsive to HAL-PDT. Many
other histone 1 forms were affected by HAL-PDT, thus it is
difficult to speculate if HIST1H1C is directly responsible
of the deadly effect of HAL-PDT. A further pursuit of the
effects of this isoform with respect to translocation and
mechanism of action awaits future studies, as does a more
detailed elucidation of the roles of various other histone
members. The verification of three histone 1 genes
(among them HIST1H1C) and one histone 2 gene
showed good agreement between RT-PCR and microar-
rays (Fig. 5).
Real-time PCR-based verification of HAL-PDT effectFigure 5
Real-time PCR-based verification of HAL-PDT effect. Nine selected genes – HIST1H1C, HIST1H2AM, HIST1H3C, 
HIST2H2AB, MT1B, MT1G, mitochondrial encoded genes (mito), mito-CYB, mito-ND2 and mito-ND5- were assessed for 
expression (relative mRNA level) at 1 h, 2 h and 4 h after HAL-PDT by real time PCR using the housekeeping RPLPO and TBP 
genes as reference genes. The fold change in gene expression (∆∆Ct) in photochemically treated samples compared to non-
treated controls was calculated and presented as the mean ± St. Dev (A). The fold-changes obtained by the microarray analysis 
for the selected genes are presented for comparison. Fold-change of three repeated experiments presented as the mean ± St. 
Dev (B). Correlation factors for arrays and RT-PCR verified genes were 0.77; 0.99 and 0.85 for 1 h, 2 h and 4 h respectively.Page 7 of 20
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The family of metallothioneins was highly represented as
differentially expressed (10 genes) (Fig. 6). Metal-
lothioneins (MTs) are a family of cysteine-rich proteins
with high affinity for metals. MTs are known as scavengers
of free oxygen radicals [59]. It has been shown that MTs
may protect DNA from Cu-induced damage by free radi-
cals through sequestering of copper, and thus prevents its
participation in redox reactions [60]. Previous studies
have also revealed that MTs can protect cells from apopto-
sis induced by oxidative stress and metals [59,61]. Since
PDT-induced cellular damage is mainly due to free oxygen
radicals [2,6], significant over-expression of the MT genes
may indicate a protective role from the HAL-PDT-induced
oxidative stress. This suggests that MTs may play a role in
regulating apoptosis, and that modulation of MT expres-
sion may provide a strategy for altering cellular resistance
to chemotherapeutic compounds [62] as well as PDT. The
MT1B gene that was selected for verification showed good
agreement between RT-PCR and arrays, while the expres-
sion of MT1G gene measured by arrays was somewhat
lower than RT-PCR (Fig. 5).
Late responses
Contrary to early responses, the number of altered genes/
probes increased sharply to a total of 15,762 probes
Cluster of metalothionein genes that were significantly altered in response to HAL-PDTFigure 6
Cluster of metalothionein genes that were significantly altered in response to HAL-PDT. Horizontal stripes represent genes 
and columns show treatment protocols. The log2-fold changes of gene ratios are color coded as shown in the bar. The three 
different columns represent repeated microarray experiments.Page 8 of 20
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the massive disturbances in the transcriptome within the
pro-apoptotic cells. The proportion of genes with up-reg-
ulated expression decreased to 41.1% at 4 h, compared to
82.9% of up-regulated genes at early response. Since the
destructive PDT dose likely causes high levels of oxidative
stress, we cannot neglect that the high number of altered
genes might likely indicate random transcriptome
changes, caused by direct oxidation of non-specific
mRNAs [63]. RNAs are reported to be more sensitive to
photodynamic degradation than DNA [56], especially
since most RNAs are cytoplasmic and exposed to higher
ROS concentrations. In the case of RNA molecules them-
selves are photooxidative targets, one could expect that
the mRNA transcripts would be damaged randomly and
not bind to the specific probes on microarrays. As a result,
the expression of genes will be measured as down regu-
lated compare to untreated cells. To explore whether the
observed RNA down-regulation at 4 h was direct and non-
specific, or targeted, we performed a Gene Ontology and
KEGG analysis. We observed that down-regulated genes
contributed significantly in GO enriched groups within
the total of differentially expressed genes (Table 1, 2).
While up-regulated genes scored in other GO groups, a
number of enriched extra-nuclear processes, especially
mitochondrial, were present when down-regulated genes
were scored. However, since HAL, the mitochondrial
localizing sensitizer was used in the study [43,64-67], the
direct effect on mitochondria was expected. Furthermore,
enriched GO processes of up-regulated genes included
both nuclear and extra-nuclear processes, such cytoskele-
ton, junctions and adhesion. Notably, because of the
direct PDT effect to cytoskeleton, well-known house keep-
ing proteins such actin or tubulin that is widely used for
the quantitation of western data would not be representa-
tive controls. Thus, for western blots, the total protein
content was used as a measure, by staining the gels after
electrophoresis and signals normalized against total pro-
tein content. Interestingly, genes encoded proteins in the
porphyrin metabolism were stimulated, indicating cellu-
lar response to excessive porphyrin production after the
transfection with HAL, which is a heme precursor. Among
these genes, 7 different UDP glucuronosyltransferase 1
and 2 family genes were induced. These are of major
importance in heme degradation [68,69]. The gene ontol-
ogy analysis suggested that the cell commitment to apop-
tosis was directly reflected in the transcriptome in a
specific manner, and not random changes.
Oxidative stress/mitochondria
A total of 639 probes (418 unique Entrez gene IDs) from
genes relevant to mitochondrial function were identified
as altered, of which 78.1% were down-regulated. These
genes encoded components of the mitochondrial enve-
lope, the mitochondrial membrane, inter membrane,
lumen and ribosome, as well as the proton-transporting
ATPase complex. The mitochondrial localization of ALA
or HAL-induced protoporphyrin-IX (PpIX) has been
established [43,64-67]. The ultrastructural alterations of
the mitochondria, in addition to higher percentages of
cells losing the mitochondrial transmembrane potential,
was reported following ALA-PDT [42,65,67]. A total of
101 genes altered by HAL-PDT were identified as being
involved in oxidative phosphorylation (Table 1). This
gene ontology group was the group most significantly (p
= 9.1E-10) enriched among all gene groups. A total of 32
genes from the ATP synthesis coupled electron transport
were found to be altered, the majority being down-regu-
lated. This is consistent with previously published data,
where ATP levels were found to be decreased at both 1 and
4 h after ALA-PDT [65]. Furthermore, dysregulation of the
Table 1: Enriched KEGG pathways in the list of differentially 
expressed genes at 4 h after HAL-PDT
KEGG Pathway Gene 
Count
% P-Value*
Total/Down regulated gene list
oxidative phosphorylation 101/79 1.0 9.1E-10
ribosome 125/119 1.2 2E-07
cell cycle 72/64 0.7 0.0015
citrate cycle (TCA cycle) 22/20 0.2 0.0041
proteasome 25/25 0.2 0.0043
ATP synthesis 32/27 0.3 0.0047
rna polymerase 21/20 0.2 0.0065
ubiquitin mediated proteolysis 32/26 0.3 0.0078
purine metabolism 92/72 0.9 0.011
pyrimidine metabolism 58/49 0.6 0.017
cholera – infection 28/20 0.3 0.02
glycolysis/gluconeogenesis 40/33 0.4 0.023
phenylalanine, tyrosine and 
tryptophan biosynthesis
10/8 0.1 0.027
propanoate metabolism 26/21 0.3 0.038
insulin signaling pathway 78/59 0.8 0.044
Up-regulated gene list
ubiquinone biosynthesis 8 0.2 0.019
alzheimer's disease 10 0.2 0.022
neuroactive ligand-receptor 
interaction
74 1.5 0.027
type i diabetes mellitus 14 0.3 0.039
focal adhesion 54 1.1 0.044
fc epsilon ri signaling pathway 23 0.5 0.065
gap junction 27 0.5 0.072
long-term depression 22 0.4 0.076
adherens junction 22 0.4 0.085
porphyrin and chlorophyll 
metabolism
12 0.2 0.096
hematopoietic cell lineage 24 0.5 0.099
*The gene-enrichment of functional categories was measured by 
determining the number of genes, belonging to the functional 
group in the list of modulated genes weigh against to the total 
analysed genes on arrays (background) using Fisher Exact test.Page 9 of 20
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ance was seriously damaged. Surprisingly, a majority of
the mitochondrial nuclear encoded genes were found to
be down-regulated, while mitochondrial encoded genes
(23 genes) were found to be up-regulated at 4 h (Fig. 7).
Mitochondria are the site of many essential biochemical
reactions, an important subset of which requires proteins
encoded in the mitochondrial DNA (mtDNA). How tran-
scription of mtDNA is regulated in response to changing
cellular demands is largely unknown. Previously, it has
been reported that release of mitochondrial components
can trigger an apoptotic response. However, it was
reported that ATP depletion after mitochondrial photo-
damage does not play a role in initiation of the apoptotic
program [70]. Previously, we reported that at 4 h follow-
ing HAL-PDT nearly 80% of the cells exhibited typical
apoptotic features and that PDT caused cytosolic translo-
cation of cytochrome c and nuclear redistribution of
apoptosis-inducing factor (AIF), followed by release of
cytochrome c [43]. Here, we report that a mitochondrial
response occurs also at the transcriptional level by repress-
ing and inducing mitochondrially encoded genes. We
found various NADH dehydrogenases to be downregu-
lated at 1 h. Mitochondrially (mito-) encoded -CYB, mito-
ND2 and mito-ND5 were verified by RT-PCR, and these
were in agreement with array results (Fig. 5). Previously it
has been reported that ALA-based PDT initiate two apop-
totic processes proceeding in parallel, one representing
the mitochondrial pathway, the other involving disrup-
tion of calcium homeostasis and activation of the endo-
plasmic reticulum stress-mediated pathway [25]. In our
study, the calcium binding proteins (365 genes) had
changed expression at 4 h post HAL-PDT, confirming the
disruption of calcium homeostasis.
The combination of the cellular responses (induction of
histones and metallothioneins) in addition to induction
of mitochondrial encoded genes may indicate a partial
repair of mitochondrial and other cellular functions.
However, it is in general difficult to assess the impact of
the changes in gene expression at 4 h, as cell mortality is
the endpoint. One of the reasons could be damaged trans-
lational machinery, given that ribosomal proteins were
identified as direct targets (Tables 1, 2).
Other pathways/genes
Other gene ontology processes found to be very signifi-
cantly affected included those of the ribosome, cell cycle
genes, proteosome, ubiquitin mediated proteolysis (Table
1), as well as protein transport, and ER to Golgi vesicle
mediated transport (data not shown). This indicated that
main cellular processes, such as the cell cycle and protein
synthesis/transport were disrupted, leading to protein
degradation through ubiquitine mediated proteolysis. In
addition, the processes such pyrimidine and purine
metabolism, glycolysis/gluconeogenesis, RNA/DNA
metabolism, cellular protein metabolism, protein biosyn-
thesis scored highly among enriched gene ontology
groups indicating disruption of these processes. This
Table 2: Enriched GOTERM Cellular Component in the list of 
differentially expressed genes at 4 h after HAL-PDT
GOTERM Cellular 
Component (level 5)
Gene 
Count
% P-Value*
Total/Down regulated gene list
mitochondrion 418/345 4.1 1.1E-17
mitochondrial envelope 124/104 1.2 2.2E-07
nuclear lumen 230/196 2.2 3.5E-07
mitochondrial membrane 113/94 1.1 1.3E-06
nucleus 2001/1390 19.5 1.3E-06
mitochondrial inner membrane 95/77 0.9 2.4E-06
mitochondrial lumen 56/50 0.5 7.7E-06
ribosome 223/200 2.2 0.000023
nucleolus 74/69 0.7 0.000035
large ribosomal subunit 41/34 0.4 0.00026
nucleoplasm 157/128 1.5 0.00062
cytosolic ribosome (sensu 
Eukaryota)
32/29 0.3 0.0007
mitochondrial electron transport 
chain
32/22 0.3 0.0007
cytosolic large ribosomal subunit 
(sensu Eukaryota)
23/20 0.2 0.00074
organellar ribosome 23/20 0.2 0.0018
mitochondrial ribosome 23/20 0.2 0.0018
heterogeneous nuclear 
ribonucleoprotein complex
15/15 0.1 0.0021
spliceosome complex 44/39 0.4 0.0039
small nucleolar ribonucleoprotein 
complex
21/21 0.2 0.0046
endoplasmic reticulum lumen 15/14 0.1 0.0063
proton-transporting ATP synthase 
complex (sensu Eukaryota)
12/9 0.1 0.011
endoplasmic reticulum 291/219 2.8 0.015
small nuclear ribonucleoprotein 
complex
13/13 0.1 0.017
proton-transporting two-sector 
ATPase complex
35/26 0.3 0.018
organellar small ribosomal subunit 12/11 0.1 0.029
endoplasmic reticulum membrane 55/47 0.5 0.035
Up-regulated gene list
integral to plasma membrane 297 6.0 1.4E-06
intercellular junction 32 0.6 0.035
nucleosome 20 0.4 0.041
chromatin 38 0.8 0.044
actin cytoskeleton 47 0.9 0.14
nucleus 752 15.2 0.16
microsome 31 0.6 0.18
cytoskeleton 175 3.5 0.22
apical junction complex 15 0.3 0.33
microtubule associated complex 24 0.5 0.37
mitochondrial electron transport 
chain
10 0.2 0.4
*The gene-enrichment of functional categories was measured by 
determining the number of genes, belonging to the functional group 
in the list of modulated genes weigh against to the total analysed 
genes on arrays (background) using Fisher Exact test.Page 10 of 20
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lism is shutting down, or at least is heavily affected, as one
should expect from apoptotic cells.
Effect on alternative splicing
In our experiments, we observed that HAL-PDT resulted in
expression changes in the spliceosome complex. A total of
72 probes (44 unique Entrez gene IDs) showed significant
changes at 4 h (Table 2), while expression of 39 genes
Cluster of mitochondria encoded genes that were significantly altered in response to HAL-PDTFigure 7
Cluster of mitochondria encoded genes that were significantly altered in response to HAL-PDT. Horizontal stripes represent 
genes and columns show treatment protocols. The log2-fold changes of gene ratios are color coded as shown in the bar. The 
three different columns represent repeated microarray experiments.Page 11 of 20
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were significantly altered at early response time points.
Alternative splicing is tightly regulated in a tissue-specific
and developmental-stage-specific manner [30,71]. Since
the microarrays included constitutive and alternative
splice variant probes, we examined how many genes were
alternatively spliced in response to HAL-PDT (Table 3). A
total list of altered splice variants is presented [see Addi-
tional file 1]. Interestingly, of 32 genes with altered
expression, 24 alternatively spliced variants were down-
regulated already after 1 h. Notably, we did not detect
changes in the transcriptional level of splice factors at
early response times. However, stress-induced signaling
mechanisms that regulate pre-mRNA splicing in vivo, by
influencing the subcellular distribution of splicing factors,
have been described [72]. This type of the regulation will
not be detected by monitoring the transcription of splice
factors. The increased proportion of down-regulated alter-
natively spliced variants remained similar (70.6 and
69.2%) at 2 and 4 h, most likely signifying a dysfunction
of the splicing machinery following treatment. Further-
more, when the low fold changed variants [1–1.99] were
taken into account, the percent of down-regulated splice
variants increased to 90, 80 and 65.6, at 1, 2 and 4 h post
HAL-PDT, respectively. In contrast, in the groups of the
alternative splice variants altered by higher fold change
[≥2], the proportion of up- and down-regulated genes
were close to equal (Table 3). This indicated nonrandom
(caused by the dysfunction of splicing machinery)
changes in alternative splicing. Thus, we used GO to
uncover whether the genes with alternatively spliced vari-
ants could be mapped to particular GO groups/altered
processes (see Table 4 for GO biological processes of
altered splice variants at 4 h). Interestingly, the GO proc-
esses of altered alternative splice variants were relatively
similar to the previously scored GO groups, and included
different metabolic processes, apoptosis, cell cycle as well
as transcription. Interestingly, 5 genes had up-regulated,
and 37 had down-regulated alternative splice variants of
the genes that had transcription factor activity. Notably,
alternative splicing of pre-mRNAs encoding transcription
factors is one of the common mechanisms for generating
the complexity and diversity of gene regulation [73]. One
of the genes was identified as activating transcription fac-
tor 3 (ATF3), that had an induced alternative splice variant
at all three studies time points, while the constitutive, full-
length variant was low expressed and did not change with
the treatment. ATF3 is a member of the mammalian acti-
vation transcription factor/cAMP responsive element-
binding (CREB) protein family of transcription factors
[74]. ATF3 plays a role in determining cell fate and has
been shown to generate a variety of alternatively spliced
isoforms in response to stress [75-78]. It was demon-
strated that ATF3 (deltaZip2) isoform, but not full-length
ATF3, sensitizes cells to apoptotic cell death, partly by sup-
pressing the expression of the NF-kappaB-dependent anti-
apoptotic genes cIAP2 and XIAP. ATF3 (deltaZip2) has
further been shown to bind directly to the p65 subunit of
NF-kapaB and down-regulate the CBP/p300 recruitment
complex [78]. The sequence analysis of the detected alter-
native splice variant revealed that the alternative splice
variant induced by HAL-PDT was the ATF3 isoform
(deltaZip2), demonstrating a direct cell fate control
through alternative splicing in HAL-PDT response. Thus,
the results stress the importance of alternative splice vari-
ant mapping. If not performed, this may lead to false
interpretations of the results.
Table 3: Counts of alternative splice variants
Filtering criteria 1 h 2 h 4 h
Number of alternative spliced genes, cut off fold change ≥1 34 13 442
Number of alternative spliced genes, cut off fold change ≥2 14 2 256
Number of alternative spliced genes, cut off fold change [1–1.99] 20 10 192
Upregulated alternative variants, cut off fold change ≥1 10 2 125
Upregulated alternative variants, cut off fold change ≥ 2 7 2 101
Upregulated alternative variants, cut off fold change [1–1.99] 3 1 27
Dowregulated alternative variants, cut off fold change ≥ 1 24 9 261
Dowregulated alternative variants, cut off fold change ≥ 2 6 1 138
Dowregulated alternative variants, cut off fold change [1–1.99] 18 8 126
Alternatives up and down for the same gene, cut off fold change ≥ 1 0 2 56
Alternatives up and down for the same gene, cut off fold change [1–1.99] 0 0 17
% of down regulated alternatives, cut off fold change ≥ 1 70.6 69.2 59.0
% of down regulated alternatives, cut off fold change ≥ 2 42.9 50.0 53.9
% of down regulated alternatives, cut off fold change [1–1.99] 90.0 80.0 65.6Page 12 of 20
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platforms: cDNA and oligo microarrays
Molecular confirmation of microarray results is important
when checking for consistencies of expression measure-
ments using different methods. RT-PCR and Western blot-
ting were used for selected genes. Recently, different
microarray platforms have been reported to have a good
agreement [79,80]. Therefore, we included experiments
on one of the time points (1 h) performed on cDNA
microarrays. In agreement with oligo microarrays, top
ranking of the genes showed alteration in ATF3, CERBPB,
JUN, JUND, IER2, as well as metallothioneins and histone
coding genes (Table 5).
Conclusion
In summary, the results provided new insights into how a
PDT relevant dose alters gene expression. We confirmed
known early defense response genes, and extended these
to include the involvement also of other oxidative stress
inducible gene groups, most notably the metallothioneins
and histones. We also demonstrated that high levels of
cellular cytotoxicity had direct effects on nuclear and
mitochondrial DNA transcription levels in impairing met-
abolic processes. Furthermore, we attempted to identify
how different signaling processes may be involved in the
execution of cell death. The results indicated that mito-
chondrial damage caused by HAL-PDT modulates alterna-
tive splicing through unbalancing a vast number of
isoform equilibriums, which may be an important contri-
bution to the deadly outcome of HAL-PDT therapy.
Methods
Cell culture and PDT treatment
The human T-cell leukemia cell line, Jurkat, was main-
tained in RPMI 1640 medium containing 10% fetal calf
serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomy-
cin and 1% glutamine in a fully humidified incubator
(Nuaire US Autoflow) at 37°C with 5% CO2. In experi-
ments with PDT, 8 × 105/ml of cells were seeded in 6-well
plastic tissue-culture plates (Nunc) and incubated in the
dark for 4 h in serum-free RPMI 1640 medium containing
5 µM of hexaminolevulinate (HAL) (PhotoCure ASA,
Oslo, Norway).
Since the light penetration is undemanding for the cell
line, the light source used in the present study has a broad
spectrum with a range of 400–500 nm, fitting largely to
the maximal absorption of porphyrins derived from ALA
and its esters including HAL. Our previous studies have
shown that the combination of HAL with the light source
can kill various types of tumor cells efficiently [42,43].
The cells were exposed to light from a bank of four fluo-
rescent tubes (model 3026, Applied Photophysics, Lon-
don, UK). The fluence rate of the light reaching the cells
was 8 mW/cm2. The light doses of 80, 160 and 240 mJ/
cm2 were used to determine the cell viability. The light
dose of 160 mJ/cm2 was chosen to treat the cells used in
microarray experiments. The cells were washed twice with
medium immediately after illumination and incubated
Table 4: Enriched GOTERM Biological Process in the list of 
alternatively spliced genes
Up-regulated splice variants, 
with fold change [≥1] at 4 h
Gene Count % P-
Value*
regulation of protein metabolism 5 5.7 0.029
cellular protein metabolism 24 27.3 0.041
phosphate metabolism 9 10.2 0.097
cytoskeleton organization and 
biogenesis
5 5.7 0.16
RNA metabolism 5 5.7 0.23
biopolymer modification 12 13.6 0.27
macromolecule biosynthesis 6 6.8 0.49
Down regulated splice variants, with fold change [≥1] at 4 h
cellular lipid metabolism 15 6.4 0.0094
negative regulation of cellular 
metabolism
8 3.4 0.035
membrane lipid metabolism 6 2.6 0.042
regulation of progression through 
cell cycle
13 5.5 0.044
intracellular transport 15 6.4 0.058
biopolymer modification 33 14.0 0.06
establishment of cellular 
localization
15 6.4 0.063
DNA metabolism 15 6.4 0.073
amino acid metabolism 8 3.4 0.073
protein catabolism 7 3.0 0.1
intracellular protein transport 9 3.8 0.1
biopolymer catabolism 7 3.0 0.13
regulation of protein kinase 
activity
5 2.1 0.15
carboxylic acid metabolism 11 4.7 0.15
endocytosis 5 2.1 0.17
cofactor biosynthesis 5 2.1 0.18
steroid metabolism 5 2.1 0.18
negative regulation of cell 
proliferation
5 2.1 0.2
lipid biosynthesis 6 2.6 0.22
regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism
37 15.7 0.26
apoptosis 11 4.7 0.31
transcription 37 15.7 0.33
cellular macromolecule catabolism 7 3.0 0.36
protein complex assembly 6 2.6 0.4
protein transport 10 4.3 0.44
chromosome organization and 
biogenesis
6 2.6 0.44
vesicle-mediated transport 7 3.0 0.45
synaptic transmission 5 2.1 0.46
*The gene-enrichment of functional categories was measured by 
determining the number of genes, belonging to the functional group 
in the list of modulated genes weigh against to the total analysed 
genes on arrays (background) using Fisher Exact test.Page 13 of 20
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Cluster of spliceosome complex genes that were significantly altered in response to HAL-PDTFigure 8
Cluster of spliceosome complex genes that were significantly altered in response to HAL-PDT. Horizontal stripes represent 
genes and columns show treatment protocols. The log2-fold changes of gene ratios are color coded as shown in the bar. The 
three different columns represent repeated microarray experiments.
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washed twice with PBS before sampling.
Cell survival
Cell survival was measured by the MTS assay [81]. After
HAL-PDT, 100 µl of each sample was placed to 96-well
plastic microplates (Nunc) and incubated at 37°C for 0, 1
and 3 h, followed by the addition of 20 µl of MTS (5 mg/
ml) (Promega Corporation, Madisom, WI, USA) into each
well for an additional 1 h-incubation. The absorbance at
490 nm was measured with a microplate reader (Labsys-
tems Oy, Helsinki, Finland). The absorbance of blank
wells containing medium and MTS, but no cells, was sub-
tracted from all readings and cell survival was expressed as
the fraction of control samples.
RNA purification and labelling
Total RNA was isolated using GenElute Mammalian Total
RNA kit (Sigma, St. Louis, MO) according to the manufac-
turer's protocol. RNA concentrations were determined
with NanoDrop spectrophotometer (NanoDrop Technol-
ogies). The integrity and degree of degradation of RNAs
was calculated using Agilent 2100 Bioanalyzer (Agilent
Technologies AS). Fluorescence-labelled cDNAs were syn-
thesized from 20 µg of the total RNA using an indirect
amino allyl microarray labelling kit (Faiplay, Stratagene,
La Jolla, CA, USA) according to the manufacturer's recom-
mendations.
Oligo microarrays and their hybridization
The oligo microarrays used in this study were obtained
from The Norwegian Microarray Consortium, for details
on the arrays, we refer to [82]. The target oligos were the
HEEBO (Human Exonic Evidence Based Oligonucleotide)
set (Invitrogen). Probes included probes for constitutive,
alternative exonic; alternative spliced/skipped exons,
mitochondrial genes (mtDNA) for more details on oligos,
we refer to [83]. During analysis all probes were handled
individually, also those that encoded the same gene. The
microarray hybridization buffer (76 ul) contained each of
the labeled probes, 16 µg poly A (Amersham Pharmacia
Biotech AB), 8 µg yeast tRNA, 0.5 µg herring's sperm DNA,
5 × SSC, 0,1% SDS, 25% (v/v) formamid. Prior to hybrid-
ization, the solution was incubated for 2 min at 100°C
and then centrifuged for 2 min at 13,000. The microarray
slides were hybridised at 42°C overnight in a humid
hybridization chamber (TeleChem International, Inc.).
The slides were washed for twice in 0.5× SSC, 0.01% SDS,
and 0.06× SSC for 5 min at room temperature. The slides
were spun and dried immediately after washing.
The microarray experiment design was based on competi-
tive hybridizations of HAL-PDT treated cells vs untreated.
Total RNA was harvested from triplicate samples of
treated and non-treated cells at 1, 2 and 4 h after HAL-
PDT. Three replicated hybridization were performed for
each time point.
Table 5: Ranking cDNA and Oligo microarray detected genes
Locus Link Gene Symbol Gene Name Heebo Rank cDNA Rank
467 ATF3 Activating transcription factor 3 16 7
4490 MT1B Metallothionein 1B (functional) 29 152
8349 HIST2H2BE Histone 2, H2be 41 180
3725 JUN V-jun sarcoma virus 17 oncogene homolog (avian) 44 60
3727 JUND Jun D proto-oncogene 51 20
9592 IER2 Immediate early response 2 65 154
8334 HIST1H2AC Histone 1, H2ac 77 41
3021 H3F3B H3 histone, family 3B (H3.3B) 113 97
4495 MT1G metallothionein 1G 116 158
3006 HIST1H1C Histone 1, H1c 266 128
2781 GNAZ Guanine nucleotide binding protein (G protein), alpha z polypeptide 282 72
1051 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 295 18
6428 SFRS3 Splicing factor, arginine/serine-rich 3 331 67
10957 PNRC1 Proline-rich nuclear receptor coactivator 1 342 84
5366 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 354 21
3251 HPRT1 Hypoanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) 530 176
168374 ZNF92 Zinc finger protein 92 (HTF12) 542 33
7128 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 596 134
5475 PPEF1 Protein phosphatase, EF hand calcium-binding domain 1 731 153
58483 C9orf27 Chromosome 9 open reading frame 27 766 146Page 15 of 20
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The cDNA microarrays used in this study were obtained
from The Norwegian Microarray Consortium, for details
on the arrays, we refer to [82]. The targets, approximately
15.000 unique I.M.A.G.E cDNA clones were from ResGen
40 k set. The hybridization volume of 110 µl consisted of:
8–10 µl of each of the labelled probes, 16 µg poly A
(Amersham Biosciences), 15 µg human Cot-1 DNA (Inv-
itrogen) and 85–90 µl of Microarray Hybridization Buffer
#1 from Ambion (Austin, TX). The final mix was heated
for 2 min at 100°C and after spinning down it was
applied on a microarray. A hybridization station
(Genomic Solutions, Inc., Ann Arbor, MI) was used for
hybridization and wash, the details on hybridizations and
wash can be found [82].
Data preparation and analysis
Slides were scanned using an Agilent Microarray scanner
(Agilent Biotechnologies). The quantitative measure-
ments of the fluorescence images were performed by the
software GenePix 4000B (Axon Instruments, Union City,
CA). The images (TIFF files) and extracted raw data (GRP
files) were stored in a BASE 1.2.15 database [84]. The
spots that were technically flawed or flagged automati-
cally by the GenePix software, spots with a diameter less
than 60 µm were removed from the data of each microar-
ray. The genes were preserved signal-to-noise ratio in one
of the channel was equal or higher then 3 removing uncer-
tain spots. Background-subtracted intensities less than
one times the sdtev of the local background were assigned
this value to avoid zero or negative values in the ratio cal-
culations. Moreover, systematic errors were corrected by
normalizing the data using a locally weighted scatter plot
smoother, the method of pin-based lowess[85] The genes
were preserved if the values were experimentally obtained
in more than 70% of the experimental matrix. The
weighted K-nearest neighbours method was applied for
imputation of missing values [86].
We used Limma package in R [87] to define differentially
expressed genes. As we had three groups (1, 2 and 4 h) and
three replicates in each group, the linear model fitting and
empirical Bayes methods were used for assessing differen-
tial expression. The empirical Bayes approach is equiva-
lent to shrinkage of the estimated sample variances
towards a pooled estimate, resulting in far more stable
inference when the number of arrays is small [88]. To clas-
sify a series of related t-statistics as up, down or not signif-
icant, the multiple testing across genes and contrasts (1, 2
and 4 h groups) was used. To avoid the multiple testing
problem [89] we have used Benjamine and Hochberg's
method [90] to control the false discovery rate across the
genes with restriction p < 0.05. The venn diagrams were
prepared with Limma to visualize the intersections of the
significant gene sets within groups. Hierarchical clustering
of genes for visualisation of expression patterns was per-
formed in MultiExperiment Viewer (MEV) [91]. Func-
tional classification was performed by using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID, release 2.1) online tools. The relative enrich-
ment of KEGG pathways (KEGG PATHWAY Database
(July 19, 2006)) was calculated the number of genes,
belonging to these functional categories in the list of sig-
nificantly altered genes. The gene-enrichment of func-
tional pathways measured by determining the number of
genes, belonging to the pathway in the list of significantly
altered genes weigh against to the total analysed/printed
genes on arrays (background) using Fisher Exact test. For
top raking of the genes, only 1 h post HAL-PDT experi-
ments performed cDNA and oligo arrays were taken. The
join was done using locus link IDs, so a gene appears as
ranked only if locus links IDs present for both the cDNA
and oligo significantly altered genes. Since many oligo
probes map to the same locus link, the highest-ranking
oligo probe for a particular locus link is used in the rank-
ing.
Gel electrophoresis and immunoblotting
For protein isolation, the cell pellets were lysed on ice in
1 ml of lysis buffer (0.4% w/v SDS, 5 mM EDTA, 5 mM
EGTA, 10 mM sodium pyrophosphate and 20 mM Tris-
base; pH 7.2) for 30 min, briefly sonicated, diluted 1:2 in
double strength SDS gel-loading buffer [double strength,
1% (w/v) SDS, 4.8 mM sodium deoxycholate, 10% (v/v)
mercaptoethanol, 1% (v/v) Igepal CA-630, ~0.1% (w/v)
Bromophenol Blue, 13,4% (v/v) glycerol and 120 mM
Tris/HCl, pH 6.8] and boiled for 5 min at 95°C. After
measuring the protein contents of the extracts with the
BCA protein assay kit from Pierce (Rockford, USA) [92],
10 µg of samples were separated by SDS gel electrophore-
sis for 40 min at 200 V in 10% polyacrylamide gels con-
taining 0.1% SDS. Molecular weight markers were
included in all gels. Gel-separated proteins were trans-
ferred to nitrocellulose blotting membranes using a semi-
dry transfer unit (Bio-Rad Laboratories, Hercules, CA,
USA) with Towbin's blotting buffer (192 mM glycine,
20% methanol and 25 mM Tris-base; pH 8.3). The mem-
branes were blocked by overnight incubation with 5% dry
milk in TBS containing 0.2% Tween-20 (TBS-T) at 4°C,
and washed three times for 10 min each in TBS-T. For
detection of proteins, the membranes were incubated
with the antibodies of MYC, ATF3 and JUN (diluted
1:1000 in TBS-T) overnight at 4°C, washed three times
with TBS-T and incubated with the respective anti-rabbit
or mouse-horseradish peroxidase-conjugated secondary
antibodies (diluted 1:2000 in TBS-T) for 1 h at room tem-
perature before being visualized by chemiluminescence
using an ECL Western Detection Kit (Amersham Bio-
sciences). To verify optimal blotting condition, the
remaining proteins in the polyacrylamide gels were rou-Page 16 of 20
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Coomassie blue R350, 20% (v/v) methanol, and 10% (v/
v) acetic acid) for 2 hours and excess staining was
removed by using a destaining solution (50% (v/v) meth-
anol in water with 10% (v/v) acetic acid) over night.
RT-PCR
The same source of total RNAs (as in the microarray exper-
iments) was used for real-time RT-PCR validation of
selected genes. cDNA was synthesized from 1 µg DNase I-
treated RNA using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA). The cDNA solution was diluted 1:3 or
1:6 with nuclease-free water. Real-time PCR was per-
formed using the iQ SYBR Green supermix (Bio-Rad) and
specific primer pairs for the selected genes (specified in
Fig. 5 and Table 6). Primers were designed using the soft-
ware Primer Express 2.0 (Applied Biosystems, Foster City,
CA). For each sample the following mix (was prepared: 10
µl cDNA, 30 µl iQ SYBRGreen Supermix, 300 nM of each
primer (MWG Biotech AG, Germany) and nuclease-free
water to a final volume of 60 µl. Aliquots of 25 µl were
distributed in two wells on the PCR plate. Real-time PCR
reactions were run on an iCycler (Bio-Rad) with the fol-
lowing amplification protocol: 3 min initial denaturation
at 95°C, 50 cycles of 10 s denaturation at 95°C and 35 s
annealing/extension at 60°C. A final melt curve analysis
was included to verify that one specific product was
obtained in each reaction. The fold changes in the relative
gene expression were calculated using the Gene Expres-
sion Macro, version 1.1 (Bio-Rad). Calculations were
based on the ∆∆Ct method, in which the threshold cycle
number (Ct) for each studied gene in each sample were
normalised to the Ct-value of the reference gene in the
same sample. As a reference gene we used human acidic
ribosomal phosphoprotein P0 (RPLPO) and TATA bind-
ing protein (TBP). Both refrence genes were tested and
showed not to be affected by the photodynamic treat-
ment. The normalized values (∆Ct) in the control sample
were given value of 1, and the fold-change between the
photodynamic treated samples and the controls were cal-
culated accordingly.
Splicing analysis
A program was written to create a concordance between
locuslink IDs and HEEBO constitutive and alternative
exon probes, using annotation information provided with
the HEEBO probe set. This concordance grouped each
locuslink ID with the oligo IDs of the probes targeting the
exons contained within the locus.
For a each locus L, we applied a test to determine if there
was a difference in expressed spliced isoforms between the
treated and reference sample. At a hybridization at a given
timepoint, we searched for at least one probe A derived
from an alternatively expressed exon in L such that 1) The
absolute value of log2ratio (A) was above a given thresh-
old (fold change of PDT treated vs. none treated controls
by 1 and 2) there existed a probe C in L from derived from
a constitutive exon such that the absolute value of the dif-
ference between the log2ratios of A and C was equal to or
greater than 1. Thus, for each hybridization, we found a
(possibly empty) set of alternatively-expressed exon
probes for each locus L. Since we performed three hybrid-
izations are each timepoint, we required at least two of the
three to agree in their results. Specifically, we required that
there be a non-empty intersection between the set of alter-
natively-expressed exon probes from at least two experi-
ments at the timepoint.
Table 6: Primers for RT-PCR
Gene Symbol Primer
HIST1H2AM Forward primer: 5' TAGGCCACAGGTCGTTTTACCA
Reverse primer: 5' GGAAATTGGAGCCCAGCTCTAG
HIST1H3C Forward primer: 5' AAGTCCACCGAGCTGCTGAT
Reverse primer: 5' AACGCAGGTCGGTTTTGAAG
HIST2H2AB Forward primer: 5' CATCATCCCTCGCCATCTG
Reverse primer: 5' AATGGTGACACCCCCGAGTA
MT1B Forward primer: 5' GCAAGAAGTGCTGCTGCTCTT
Reverse primer: 5' TGATGAGCCTTTGCAGACACA
MT1G Forward primer: 5' CCTGTGCCGCTGGTGTCT
Reverse primer: 5' TGCAGCCTTGGGCACACT
HIST1H1C Forward primer: 5' GCGGCCACTGTAACCAAGA
Reverse primer: 5' AGCAGCACTTTTGGCAGCTT
MT-ND5 Forward primer: 5' GATGATACGCCCGAGCAGAT
Reverse primer: 5' AGGCGAGGATGAAACCGATAT
MT-ND2 Forward primer: 5' TCCAGCACCACGACCCTACT
Reverse primer: 5' TTCGATAATGGCCCATTTGG
MT-CYB Forward primer: 5' CCCTAGCCAACCCCTTAAACA
Reverse primer: 5' GGACGGATCGGAGAATTGTGPage 17 of 20
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